Baxter (NYSE:BAX) announced earlier this month it tapped former Medtronic (NYSE:MDT) senior VP of medicine and tech Stephen Oesterle for its board of directors, bringing the total seats on the board to 12.
Oesterle moved to the venture capital firm New Enterprise Associates last Sept from his position at Medtronic.
Before moving to NEA, Oesterle served as senior veep of medicine and tech and a member of the executive committee at Medtronic, which he joined in 2002 and in 2015. Dr. Oesterle has served on more than 20 boards as a director or observer during his time at Medtronic. He also served as director of the invasive cardiology services as Massachusetts General Hospital and Stanford.
“We are excited to welcome Steve to Baxter’s board His deep experience in leveraging technology to address global healthcare needs, coupled with his differentiated expertise as a former practicing physician, enhances our current board membership and supports our goals for patient-focused, innovation-driven growth,” CEO José Almeida said in an SEC filing.
Royal Philips (NYSE:PHG) today announced a slew of changes to its executive roster, tapping Jeroen Das as its new innovation & strategy chief, Carla Kriwet as its new connected care & health informatics biz lead and Ronald de Jong as its HR global head.
“In 2016, Philips made significant progress with its strategic transformation to a focused leader in health technology and we have good momentum. Looking ahead, there is an opportunity for us to accelerate Philips’ transition to a customer-centric solutions company, and further leverage advanced informatics, artificial intelligence and the internet of things into our health propositions and our way of working. I am convinced that with the new responsibilities of Jeroen, Carla and Ronald within Philips’ Executive committee, we will be able to accelerate on our journey,” CEO Frans van Houten said in a press release.
Dexcom Inc. (NSDQ:DXCM) said last week its CFO and senior VP Jess Roper will resign, effective April 1, 2017. The exit is not the result of a disagreement with Dexcom, according to an SEC filing, nor is it related to the operations, policies, practices or finances of the company.
Roper will be replaced by Kevin Sun, who will serve as interim CFO. Sun has served as finance VP since February 2016, and prior to that served as finance senior director and finance director at the company.
Nobilis Health said earlier this month it picked former St. Jude Medical Americas division CFO David young as its new chief financial officer, succeeding Kenny Klein. Before his time at St. Jude, Young acted as finance VP at Thermo Fisher Scientific, and as finance VP at Cardinal Health prior to that.
“We are excited to welcome David to the leadership team at Nobilis. He will unquestionably make an immediate impact on our financial operations as we continue to grow nationally. We have expanded our markets and facilities over the last three years which has created the need for us to bring deeper experience to the finance team. David brings the track record of a successful chief financial officer in managing national level portfolios along with his experience as a seasoned operations executive. His skills and integrity are important attributes that he brings to the executive team as Nobilis continues its aggressive growth. David’s primary focus will be to manage Nobilis’ bottom line to keep up with our rapid growth. Nobilis will continue to bring in experienced executives to manage its rapidly growing national presence,” CEO Harry Fleming, Chief Executive Officer of Nobilis.
Klein will stay on at Nobilis and serve in a finance leadership role for the company’s hospital division.
Pennsylvania University’s Penn Center said last week it snagged former Medtronic aortic, peripheral and vascular chief medical officer Mark Turco as its new chief innovation and corporate outreach officer.
“Mark’s prior accomplishments and background in both the medical field and the private and public sectors are of tremendous value to our organisation, and he brings a unique perspective to PCI and our executive leadership team. I am really delighted to welcome Mark on board, and we are all looking forward to working closely with him to build additional strategic relationships between the Penn community and industry to help better connect our faculty with corporate and other possible partners,” assistant research vice-provost & PCI managing director John Swartley said in a prepared statement.
“I am looking forward to working with Penn’s expert faculty and other members of its innovation community as well as external partners to facilitate and extend new and ongoing collaborations to translate Penn ideas into products and services that benefit patients and society. I am truly excited to bring my skills and experience as a physician, scientist and business development leader to further support and extend the university’s innovation and commercialisation goals,” Turco said in a press release.